I presume ABT-450 will command at least 1/3 of the nominal value of ABBV’s 3-DAA regimen. Ribavirin is available as a cheap generic in all jurisdictions, so whether ribavirin ends up being in the regimen for a given patient group probably won't alter the nominal value of the 3 DAA's to a material degree.
ABT's dispute with CATG regarding Humira royalties focused on the question of who had to pay the royalties to CAT's own licensors—see #msg-8243763. No such complication exists in ENTA's case, as far as I know.
Market Data 
Markets 
AI
